Quinn Deveraux
Nessuna posizione attualmente
Profilo
Quinn Deveraux was the founder of Inhibrx LP, established in 2010, where he held the title of Chief Scientific Officer.
He was also the founder of Inhibrx, Inc., established in 2010, where he held the title of Executive Vice President-Early Research until 2021.
Dr. Deveraux's former job was as a Senior Research Scientist at Novartis Institute for Functional Genomics, Inc. Dr. Deveraux earned a doctorate degree from the University of Utah School of Medicine.
Precedenti posizioni note di Quinn Deveraux
| Società | Posizione | Fine |
|---|---|---|
| INHIBRX, INC. | Fondatore | 01/06/2021 |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Inhibrx LP
 Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Fondatore | - |
Formazione di Quinn Deveraux
| University of Utah School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| INHIBRX, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Inhibrx LP
Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Health Technology |
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
- Borsa valori
- Insiders
- Quinn Deveraux
